Taysha Gene Therapies Long Term Debt 2020-2024 | TSHA
Taysha Gene Therapies long term debt from 2020 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Taysha Gene Therapies Annual Long Term Debt
(Millions of US $) |
| 2023 |
$41 |
| 2022 |
$38 |
| 2021 |
$37 |
| 2020 |
$ |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Long Term Debt
(Millions of US $) |
| 2024-09-30 |
$43 |
| 2024-06-30 |
$38 |
| 2024-03-31 |
$41 |
| 2023-12-31 |
$41 |
| 2023-09-30 |
$39 |
| 2023-06-30 |
$38 |
| 2023-03-31 |
$38 |
| 2022-12-31 |
$38 |
| 2022-09-30 |
$38 |
| 2022-06-30 |
$38 |
| 2022-03-31 |
$37 |
| 2021-12-31 |
$37 |
| 2021-09-30 |
$28 |
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.434B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
